| scholarly article | Q13442814 |
| P2093 | author name string | Zheng Zhang | |
| Vasileios C Kyttaris | |||
| George C Tsokos | |||
| P2860 | cites work | Elevation of proinflammatory cytokine (IL-18, IL-17, IL-12) and Th2 cytokine (IL-4) concentrations in patients with systemic lupus erythematosus | Q73086966 |
| IL-12 deficiency in MRL-Fas(lpr) mice delays nephritis and intrarenal IFN-gamma expression, and diminishes systemic pathology | Q73149267 | ||
| Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice | Q79317500 | ||
| IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis | Q79755041 | ||
| IL-17 and Th17 Cells | Q27860566 | ||
| Molecular antagonism and plasticity of regulatory and inflammatory T cell programs | Q29619478 | ||
| Interleukin-17/interleukin-17 receptor-mediated signaling is important for generation of an optimal polymorphonuclear response against Toxoplasma gondii infection | Q33556845 | ||
| Pathogenic anti-DNA autoantibody-inducing T helper cell lines from patients with active lupus nephritis: isolation of CD4-8- T helper cell lines that express the gamma delta T-cell antigen receptor | Q33787097 | ||
| Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease | Q34602392 | ||
| Interleukin 17-producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice | Q34729932 | ||
| Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity. | Q34765324 | ||
| Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys | Q34892862 | ||
| An essential role for IL-17 in preventing pathogen-initiated bone destruction: recruitment of neutrophils to inflamed bone requires IL-17 receptor-dependent signals | Q35804523 | ||
| Clinical presentation and monitoring of lupus nephritis | Q36054828 | ||
| Current treatment of lupus nephritis | Q37168027 | ||
| An overview of IL-17 function and signaling | Q37243055 | ||
| T cell receptor alpha/beta expressing double-negative (CD4-/CD8-) and CD4+ T helper cells in humans augment the production of pathogenic anti-DNA autoantibodies associated with lupus nephritis | Q44381577 | ||
| Differential roles of interleukin-17A and -17F in host defense against mucoepithelial bacterial infection and allergic responses. | Q44894318 | ||
| Activated T lymphocytes in the peripheral blood of patients with systemic lupus erythematosus induce B cells to produce immunoglobulin | Q68098890 | ||
| Phenotypic and functional analyses on T-cell subsets in lymph nodes of MRL/Mp-lpr/lpr mice | Q70398689 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 3160-3169 | |
| P577 | publication date | 2009-08-05 | |
| P1433 | published in | Journal of Immunology | Q3521441 |
| P1476 | title | The role of IL-23/IL-17 axis in lupus nephritis | |
| P478 | volume | 183 |
| Q55163735 | Aberrant T Cell Signaling and Subsets in Systemic Lupus Erythematosus. |
| Q36426921 | Absence of CD59 exacerbates systemic autoimmunity in MRL/lpr mice |
| Q37658524 | Accelerated atherosclerosis in SLE: mechanisms and prevention approaches |
| Q50974310 | Activity of childhood lupus nephritis is linked to altered T cell and cytokine homeostasis. |
| Q34066698 | An essential role of interleukin-17 receptor signaling in the development of autoimmune glomerulonephritis |
| Q84996896 | Anti-ribosomal P protein antibody induces Th1 responses by enhancing the production of IL-12 in activated monocytes |
| Q36026299 | Autoantigen TRIM21/Ro52 as a Possible Target for Treatment of Systemic Lupus Erythematosus |
| Q34451062 | Autocrine IFNγ controls the regulatory function of lymphoproliferative double negative T cells |
| Q37058781 | Biomarkers in systemic lupus erythematosus: challenges and prospects for the future |
| Q52620149 | CD11b Activity Modulates Pathogenesis of Lupus Nephritis. |
| Q85046829 | CD3 mAb treatment ameliorated the severity of the cGVHD-induced lupus nephritis in mice by up-regulation of Foxp3+ regulatory T cells in the target tissue: Kidney |
| Q48216696 | CD74 Deficiency Mitigates Systemic Lupus Erythematosus-like Autoimmunity and Pathological Findings in Mice. |
| Q40846193 | CXCR5 is critically involved in progression of lupus through regulation of B cell and double-negative T cell trafficking |
| Q37726675 | CaMK4-dependent activation of AKT/mTOR and CREM-α underlies autoimmunity-associated Th17 imbalance |
| Q35082332 | Calcium signaling in systemic lupus erythematosus T cells: a treatment target |
| Q38366479 | Contribution of B-1a cells to systemic lupus erythematosus in the NZM2410 mouse model |
| Q34080154 | Cutting edge: IL-23 receptor deficiency prevents the development of lupus nephritis in C57BL/6-lpr/lpr mice |
| Q37176288 | Cyclin-dependent kinase inhibitor Cdkn2c regulates B cell homeostasis and function in the NZM2410-derived murine lupus susceptibility locus Sle2c1 |
| Q37751877 | Cytokines and their roles in the pathogenesis of systemic lupus erythematosus: from basics to recent advances |
| Q54524078 | Decreased apopto-phagocytic gene expression in the macrophages of systemic lupus erythematosus patients. |
| Q37498557 | Deficient leptin signaling ameliorates systemic lupus erythematosus lesions in MRL/Mp-Fas lpr mice |
| Q35806064 | Deletion of IL-18 Expression Ameliorates Spontaneous Kidney Failure in MRLlpr Mice |
| Q92097039 | Design and application of single-cell RNA sequencing to study kidney immune cells in lupus nephritis |
| Q35186959 | Double negative (DN) αβ T cells: misperception and overdue recognition |
| Q53306406 | Down-regulation of expression of retinoid acid-related orphan receptor C (RORC) in systemic lupus erythematosus. |
| Q36342930 | Dual signaling by innate and adaptive immune receptors is required for TLR7-induced B-cell-mediated autoimmunity |
| Q30405805 | Dysregulated CD4+ T cells from SLE-susceptible mice are sufficient to accelerate atherosclerosis in LDLr-/- mice |
| Q33923351 | Dysregulated balance of Th17 and Th1 cells in systemic lupus erythematosus |
| Q55475388 | Ectonucleotidase-Mediated Suppression of Lupus Autoimmunity and Vascular Dysfunction. |
| Q36373858 | Effector T-cell subsets in systemic lupus erythematosus: update focusing on Th17 cells |
| Q36953169 | Effects of 1,25-dihydroxyvitamin D3 on IL-17/IL-23 axis, IFN-γ and IL-4 expression in systemic lupus erythematosus induced mice model |
| Q87292752 | Endogenous interleukin (IL)-17A promotes pristane-induced systemic autoimmunity and lupus nephritis induced by pristane |
| Q54546565 | Enhanced interferon regulatory factor 3 binding to the interleukin-23p19 promoter correlates with enhanced interleukin-23 expression in systemic lupus erythematosus. |
| Q83845321 | Expressions of IL-22 in circulating CD4+/CD8+ T cells and their correlation with disease activity in SLE patients |
| Q34769749 | FcRγ controls the fas-dependent regulatory function of lymphoproliferative double negative T cells |
| Q38456502 | Gene polymorphisms of interleukin-17 and interleukin-17 receptor are associated with end-stage kidney disease |
| Q38396871 | Genetics and pathogenesis of systemic lupus erythematosus and lupus nephritis |
| Q36387092 | Glucose Oxidation Is Critical for CD4+ T Cell Activation in a Mouse Model of Systemic Lupus Erythematosus. |
| Q35078183 | IL-17 and IL-23 in lupus nephritis - association to histopathology and response to treatment |
| Q93222504 | IL-17 in Renal Immunity and Autoimmunity |
| Q37727813 | IL-17 in systemic lupus erythematosus |
| Q37838092 | IL-17-producing T cells in lupus nephritis |
| Q37983096 | IL-17/IL-17 receptor system in autoimmune disease: mechanisms and therapeutic potential |
| Q38040748 | IL-17: a new actor in IFN-driven systemic autoimmune diseases |
| Q35238914 | IL-17A increases ADP-induced platelet aggregation. |
| Q87887570 | IL-17C/IL-17 Receptor E Signaling in CD4+ T Cells Promotes TH17 Cell-Driven Glomerular Inflammation |
| Q34053939 | IL-2 protects lupus-prone mice from multiple end-organ damage by limiting CD4-CD8- IL-17-producing T cells |
| Q37777456 | IL-23: A Promising Therapeutic Target for Systemic Lupus Erythematosus |
| Q37243199 | Immune and inflammatory role in renal disease. |
| Q91847805 | Immunological pathogenesis and treatment of systemic lupus erythematosus |
| Q51752326 | Increased IL-17 and IL-21 producing TCRαβ+CD4-CD8- T cells in Chinese systemic lupus erythematosus patients. |
| Q34153057 | Increased expression of costimulatory markers CD134 and CD80 on interleukin-17 producing T cells in patients with systemic lupus erythematosus. |
| Q26823647 | Inflammatory cytokines in systemic lupus erythematosus |
| Q30429445 | Interleukin 17 in vascular inflammation |
| Q37553560 | Interleukin-1 accounts for intrarenal Th17 cell activation during ureteral obstruction. |
| Q36641593 | Interleukin-17 causes Rho-kinase-mediated endothelial dysfunction and hypertension |
| Q36676453 | Interleukin-17 cytokines are critical in development of fatal lupus glomerulonephritis |
| Q64109685 | Lack of IL-17 Receptor A signaling aggravates lymphoproliferation in C57BL/6 lpr mice |
| Q39244069 | Laquinimod delays and suppresses nephritis in lupus-prone mice and affects both myeloid and lymphoid immune cells |
| Q37728466 | Ly108 expression distinguishes subsets of invariant NKT cells that help autoantibody production and secrete IL-21 from those that secrete IL-17 in lupus prone NZB/W mice |
| Q64283956 | Mechanisms of hypertension in autoimmune rheumatic diseases |
| Q37612885 | Metabolic Factors that Contribute to Lupus Pathogenesis |
| Q36177195 | Metabolic regulation of organelle homeostasis in lupus T cells |
| Q27010174 | Modulatory function of invariant natural killer T cells in systemic lupus erythematosus |
| Q35059002 | Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. |
| Q37776362 | Neutrophils: game changers in glomerulonephritis? |
| Q34193426 | Normalization of the lymph node T cell stromal microenvironment in lpr/lpr mice is associated with SU5416-induced reduction in autoantibodies |
| Q39164953 | Novel Treatments in Lupus |
| Q59798146 | Novel Treatments in Lupus |
| Q28396263 | Nuclear Factor Erythroid 2-related Factor 2 Deficiency Exacerbates Lupus Nephritis in B6/lpr mice by Regulating Th17 Cell Function |
| Q51477256 | Oral administration of artemisinin analog SM934 ameliorates lupus syndromes in MRL/lpr mice by inhibiting Th1 and Th17 cell responses. |
| Q35182476 | Paradoxical effects of all-trans-retinoic acid on lupus-like disease in the MRL/lpr mouse model |
| Q33664927 | Pathogenesis of human systemic lupus erythematosus: recent advances |
| Q28080571 | Pathogenesis of renal disease in systemic lupus erythematosus--the role of autoantibodies and lymphocytes subset abnormalities |
| Q47722937 | Pathological significance and regulatory mechanism of lymphotoxin β receptor overexpression in T cells of patients with systemic lupus erythematosus |
| Q41416393 | Phage display-derived human antibodies in clinical development and therapy |
| Q34090173 | Phosphorylation of IRF4 by ROCK2 regulates IL-17 and IL-21 production and the development of autoimmunity in mice |
| Q37019903 | Pro-inflammatory self-reactive T cells are found within murine TCR-αβ(+) CD4(-) CD8(-) PD-1(+) cells. |
| Q64939151 | REDD1/autophagy pathway promotes thromboinflammation and fibrosis in human systemic lupus erythematosus (SLE) through NETs decorated with tissue factor (TF) and interleukin-17A (IL-17A). |
| Q51048914 | RORγt expression in Tregs promotes systemic lupus erythematosus via IL-17 secretion, alteration of Treg phenotype and suppression of Th2 responses. |
| Q37902251 | Recent advances in cytokines in cutaneous and systemic lupus erythematosus |
| Q35122990 | Reduced B lymphoid kinase (Blk) expression enhances proinflammatory cytokine production and induces nephrosis in C57BL/6-lpr/lpr mice |
| Q40508654 | Regulation of Interleukin-17 Production |
| Q51036730 | Remission of systemic lupus erythematosus disease activity with regulatory cytokine interleukin (IL)-35 in Murphy Roths Large (MRL)/lpr mice. |
| Q35829864 | Roles of pro- and anti-inflammatory cytokines in the pathogenesis of SLE |
| Q53577471 | Ruxolitinib Attenuates Cutaneous Lupus Development in a Mouse Lupus Model. |
| Q36585774 | Self double-stranded (ds)DNA induces IL-1β production from human monocytes by activating NLRP3 inflammasome in the presence of anti-dsDNA antibodies |
| Q33437451 | Serum 25-OH vitamin D level in treatment-naïve systemic lupus erythematosus patients: Relation to disease activity, IL-23 and IL-17. |
| Q36683150 | Serum IL-10 from systemic lupus erythematosus patients suppresses the differentiation and function of monocyte-derived dendritic cells |
| Q39043261 | Serum interleukin-17 in Egyptian children with systemic lupus erythematosus: is it related to pulmonary affection? |
| Q35666611 | Serum interleukin-17 levels are associated with nephritis in childhood-onset systemic lupus erythematosus |
| Q41831402 | Signal transducer and activator of transcription (STAT) 3 inhibition delays the onset of lupus nephritis in MRL/lpr mice |
| Q53076914 | Studying cytokines of T helper cells in the kidney disease of IgA vasculitis (Henoch-Schönlein purpura). |
| Q36976397 | Suppressive oligodeoxynucleotides promote the development of Th17 cells. |
| Q58799147 | T Cell Receptor-Independent, CD31/IL-17A-Driven Inflammatory Axis Shapes Synovitis in Juvenile Idiopathic Arthritis |
| Q38816316 | T cells and IL-17 in lupus nephritis. |
| Q35214963 | T cells as a therapeutic target in SLE. |
| Q34075552 | T cells as therapeutic targets in SLE. |
| Q46325099 | T helper type 17 cells in immune-mediated glomerular disease |
| Q54312343 | TRIM28 prevents autoinflammatory T cell development in vivo. |
| Q37763951 | Targeting IL-23 in human diseases. |
| Q39201665 | Tertiary lymphoid organs in systemic autoimmune diseases: pathogenic or protective? |
| Q35189911 | Tetramers reveal IL-17-secreting CD4+ T cells that are specific for U1-70 in lupus and mixed connective tissue disease. |
| Q41703683 | Th-17 related regulatory network in the pathogenesis of Arab patients with systemic lupus erythematosus and lupus nephritis |
| Q34821636 | The NZM2410-derived lupus susceptibility locus Sle2c1 increases Th17 polarization and induces nephritis in fas-deficient mice |
| Q37726972 | The Th17 immune response in renal inflammation |
| Q34695374 | The Th17-defining transcription factor RORγt promotes glomerulonephritis |
| Q35579076 | The current concept of T (h) 17 cells and their expanding role in systemic lupus erythematosus |
| Q35691272 | The discovery and development of belimumab: the anti-BLyS-lupus connection |
| Q35294513 | The dysregulation of cytokine networks in systemic lupus erythematosus |
| Q87646214 | The fungal lactone oxacyclododecindione is a potential new therapeutic substance in the treatment of lupus-associated kidney disease |
| Q47264616 | The potential role of Th17 cells and Th17-related cytokines in the pathogenesis of lupus nephritis |
| Q37831821 | The role of Th17 lymphocytes in the autoimmune and chronic inflammatory diseases |
| Q35418333 | The role of cytokine in the lupus nephritis |
| Q35294438 | The role of cytokines in the pathogenesis and treatment of systemic lupus erythematosus |
| Q38085723 | The role of cytokines in the pathogenesis of systemic lupus erythematosus - from bench to bedside |
| Q44357234 | The role of interleukin-17 in the associations between systemic lupus erythematosus and ANCA-associated vasculitis : Comment on: systemic lupus erythematosus associated with ANCA-associated vasculitis: an overlapping syndrome? (Rheumatol Int. 2012 O |
| Q64054927 | Therapeutic Implication of SOCS1 Modulation in the Treatment of Autoimmunity and Cancer |
| Q37541469 | Tofacitinib Ameliorates Murine Lupus and Its Associated Vascular Dysfunction. |
| Q37974990 | Treatment of systemic lupus erythematosus: new advances in targeted therapy |
| Q36948466 | Treatment with anti-interleukin 23 antibody ameliorates disease in lupus-prone mice |
| Q52944545 | Type I interferon and T helper 17 cells co-exist and co-regulate disease pathogenesis in lupus patients. |
| Q35916695 | Vitamin A improve Th17 and Treg regulation in systemic lupus erythematosus |
Search more.